Elan Makes $20M Investment in Proteostasis as Part of Drug Discovery Partnership for Neurodegenerative Diseases

Irish pharma Elan is heavily investing in the drug discovery platform being developed by Cambridge biotech Proteostasis Therapeutics. The partnership is expected to identify targets and small molecule drugs to treat neurodegenerative and dementia-related disorders including ALS and Alzheimer disease.

Click here to read more.

Share this: